PharmTech Drug Digest 11.20
|Articles|December 4, 2008

Terror Attacks Postpone Mumbai Conference and Raise Concern over Outsourcing

Industry experts are predicting that last week?s terror attacks in Mumbai, India may have at minimum some short-term effects on the pharmaceutical industry outsourcing business in that region.

London, England (Nov. 27)-Industry experts are predicting that last week’s terror attacks in Mumbai, India may have at minimum some short-term effects on the pharmaceutical industry outsourcing business in that region. Already, CMP Information, part of United Business Media, has postponed the pharmaceutical conference CPhI India until next year. The conference was scheduled to take place Nov. 27 to Nov. 30; however, the group cited the “current adverse security situation” as reason for the event’s postponement. Another conference, the Drug Information Association’s 3rd Annual Meeting on Drug Discovery and Clinical Development in India, scheduled for Dec. 7-10, 2008, was also postponed until further notice.

Although no other industry decisions have been announced in the wake of the events, some fear continued instability in the region will hurt the region’s position as a viable outsourcing site. Speaking with Mumbai’s business newspaperBusiness Standard, Sujay Shetty, head of life sciences at PricewaterhouseCoopers, said: “Executives of global companies may be asked to refrain from coming to India, and many planned visits have been cancelled.”

The report also quotes Ranjit Shahani, president of Indian Merchant’s Chamber and vice-chairman and managing director of Novartis India, “Such repeated terrorist attacks will mar our business prospects, especially from Fortune 500 companies … [and] add more worries to our economic growth.”


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.